Who said any publicity is good publicity? It’s not so in the case of Phosphagenics (POH). As one of the ASX’s numerous mid to low profile biotechs it is still suffering reputational deficit ever since its well regarded and high profile CEO resigned after systematic “invoice irregularities” were uncovered. The shock in Melbourne’s biotech circles echoed for months with existential undertones.
For six years Phosphagenics (POH) has been working to prove its TPM technology can transdermally deliver therapeutic doses of drugs that until now have had no such delivery option. Transdermal delivery means the dose of a drug is absorbed through the skin.